Dr Lal PathLabs adds Illumina’s NovaSeq X to its genomics division
The NovaSeq X system, featuring Illumina’s XLEAP-SBS chemistry, can generate more than 20,000 whole genomes per year, more than double the throughput of Illumina’s previous sequencers
Dr. Lal PathLabs has expanded its genomics capabilities by adding Illumina’s NovaSeq X Series to its dedicated genomics division, Genevolve. With the integration of Illumina’s latest technology, DLPL can now deliver faster and more accurate genomic research insights.
The NovaSeq X system, featuring Illumina’s XLEAP-SBS chemistry, can generate more than 20,000 whole genomes per year, more than double the throughput of Illumina’s previous sequencers. Its speed, scale, and accuracy push the limits of what’s possible in genetic sequencing.
The addition of Illumina products adds to Genevolve’s work in next-generation sequencing (NGS), enabling DLPL to deliver actionable, AI-powered insights with greater speed and sensitivity.
Dr. Lal PathLabs and Illumina aim to engage closely with India’s medical and scientific communities to build awareness and capacity for genomics-based decision-making.
- Advertisement -